Items where Author is "Guan, Xiaodong"
Number of items: 7.
Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data:a retrospective analysis. (2024)
Naci, Huseyin and Zhang, Yichen and Woloshin, Steven and Guan, Xiaodong and Xu, Ziyue and Wagner, Anita K.
picture_as_pdf
Overall survival benefits of cancer drugs approved in China from 2005 to 2020. (2022)
Zhang, Yichen and Naci, Huseyin and Wagner, Anita K. and Xu, Ziyue and Yang, Yu and Zhu, Jun and Ji, Jiafu and Shi, Luwen and Guan, Xiaodong
picture_as_pdf
Cancer drug indication approvals in China and the United States:a comparison of approval times and clinical benefit, 2001–2020.
Wei, Yuxuan and Zhang, Yichen and Xu, Ziyue and Wang, Guoan and Zhou, Yue and Li, Huangqianyu and Shi, Luwen and Naci, Huseyin and Wagner, Anita K. and Guan, Xiaodong
picture_as_pdf
Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs.
Naci, Huseyin and Guan, Xiaodong and Woloshin, Steven and Xu, Ziyue and Wagner, Anita K.
picture_as_pdf
Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021.
Zhou, Yue and Naci, Huseyin and Chen, Dingyi and Bai, Lin and Shi, Luwen and Guan, Xiaodong and Wagner, Anita Katharina
picture_as_pdf
Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018.
Fu, Mengyuan and Naci, Huseyin and Booth, Christopher M. and Gyawali, Bishal and Cosgrove, Austin and Toh, Sengwee and Xu, Ziyue and Guan, Xiaodong and Ross-Degnan, Dennis and Wagner, Anita K.
Strength of evidence supporting cancer drug approvals in China, 2017-2021.
Zhang, Yichen and Chen, Dingyi and Fu, Mengyuan and Shi, Luwen and Naci, Huseyin and Wagner, Anita Katharina and Ross, Joseph S. and Guan, Xiaodong